Verseon wins new European patent for oral anticoagulant program

Verseon said the European Patent Office has granted a new patent covering its Precision Oral Anticoagulant program, extending protection for a drug class aimed at preventing strokes and heart attacks. The company says the compounds could offer a safer option for the hundreds of millions of cardiovascular patients who may need long-term anticoagulant therapy.

Why it matters: - Verseon says the new European patent extends intellectual property protection for its Precision Oral Anticoagulant, or PROAC, program. - The company is targeting a very large cardiovascular patient population that faces elevated stroke and heart attack risk. - Verseon says the compounds are designed to reduce clotting without increasing bleeding risk, which is the main limitation of currently available anticoagulants.

What happened: - The European Patent Office granted a new patent covering Verseon’s PROAC program. - The patent covers Verseon’s novel class of compounds for the prevention of strokes and heart attacks. - Verseon announced the patent on July 15, 2026.

The details: - Verseon says the protected compounds act through a distinct mechanism that blocks clot formation linked to strokes and heart attacks. - The company says the compounds have high selectivity against other serine proteases. - Verseon says the mechanism spares thrombin-mediated platelet activation. - That design could support long-term use alongside antiplatelet drugs, including Plavix and aspirin. - Current anticoagulants carry substantial bleeding risk when used alone, and Verseon says that risk rises sharply when combined with antiplatelet therapy. - Verseon says more than 200 million cardiovascular disease patients worldwide could benefit from safer treatment options. - UCL Professor of Cardiology John Deanfield said Verseon’s platelet-sparing anticoagulants represent an exciting precision-medicine opportunity for a large cardiovascular patient population.

Between the lines: - The patent strengthens Verseon’s intellectual property position around a drug platform that the company says uses quantum physics-driven molecular design and AI-based optimization. - Verseon is trying to differentiate its pipeline by targeting clot prevention without the bleeding tradeoff that has constrained the market for anticoagulants. - If the clinical profile matches the company’s claims, the PROAC program could fit into both standalone anticoagulant use and combination therapy with antiplatelet drugs. - Verseon’s CSO David Kita said the additional patent protection could help serve several hundred million underserved cardiovascular patients worldwide.

What's next: - Verseon will likely continue building out patent protection around the PROAC program and the wider drug discovery platform. - The company says its pipeline includes multiple novel candidates across cardiometabolic disorders and cancers. - Further development will depend on whether the compounds can maintain the promised safety and efficacy profile in clinical testing.

The bottom line: - The new European patent gives Verseon more room to advance a potentially safer anticoagulant class in a market where bleeding risk remains a major barrier to treatment.